Strainprint™ Closes USD $3 Million (Cdn.$3.8M) Series A Funding

TORONTOMay 8, 2018 /PRNewswire/ – StrainprintTM Technologies — the leader in cannabis data and analytics is pleased to announce the closing of a USD $3 Million (Cdn.$3.8 Million) non-brokered, Series A private placement. The round was led by strategic industry investor, Cesare Fazari, Chairman of Molecular Science Corp and seed investor of leading cannabis companies, Ample Organics and Hydropothecary. Mr. Fazari will also join Strainprint’s Board of Directors and will play an active role in strategic business development.  The round also includes a significant follow-on investment from NY-based, Core Strain Ltd., as well as participation from a number of Toronto-based capital funds.

Strainprint will use proceeds for talent acquisition and to rapidly expand sales and marketing of its disruptive Strainprint Analytics web platform across North America and into key international markets like Australia and Germany. The company will also continue to innovate its industry-leading outcomes-tracking mobile journal for patients with symptom-specific measurement protocols and ethics compliance, developed together with our world-class medical advisors.

Since February 2017, tens of thousands of medical cannabis patients have tracked over 500,000 medical records on Strainprint’s mobile patient journal, generating over 7 million data points on strain efficacy and patient use.  It is the largest and most granular longitudinal study of its kind and its growing by 25% per month. In addition to helping patients lead healthier lives, this medically validated data is helping to shape the entire cannabis industry by providing business intelligence, as well as treatment and product guidance for producers, retailers, clinicians, researchers, pharma, insurance and government.

“This funding round represents a key milestone for Strainprint that will allow us to capitalize on our first-mover advantage as the premier source of medical cannabis use data,” said Strainprint CEO, Andrew Muroff. “Amongst other initiatives, we plan to rapidly provision our team and SaaS products to serve international markets where imported Canadian cannabis is the primary source of available product.”

The Strainprint mobile app is available for free to patients on both iOS and Android, while web-based Strainprint Analytics is available by monthly subscription.

About StrainprintTM:
Founded in Toronto in 2016,StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR), seed2sale and Ecomm software systems.  The Strainprint App is free to patients and can be downloaded from both the iOS App and GooglePlay stores. www.strainprintanalytics.comwww.strainprint.cafacebooktwitterlinkedin

Strainprint™ Technologies Ltd. Launches Custom-Branded OEM Version of Industry-Leading Mobile Cannabis Journaling App for Canna Farms

TORONTO, Nov. 21, 2017 /CNW/ – Strainprint™ — the leader in cannabis data collection and strain efficacy reporting — is pleased to announce the release of the Canna Farms OEM version of the Strainprint mobile App. The newest custom-branded version of the Strainprint App is available exclusively for Canna Farms customers through a unique activation code.

Canna Farms is a Health Canada Licensed Producer (“LP”) of craft cannabis products, and the first ACMPR LP in British Columbia. “We are very excited about having this branded version of the Strainprint App as it will create an easy and efficient way for our customers to track their cannabis usage and determine what strains work best for them,” said Canna Farms’ President, Ray Laflamme.

In addition to helping build the Canna Farms community, the exclusive version of the App sets Canna Farms apart from other LPs. “We’re thrilled to be working with the Canna Farms team. They truly understand the value of incorporating technology to better communicate with their customers and expand their reach while using Strainprint as a key component,” said Evan Karasick, Strainprint’s Chief Product Officer.

Strainprint offers custom-branded versions of its mobile App for producers, clinics, researchers and industry. This enables rapid community development through prompted messaging and configurable loyalty engagement in compliance with Health Canada regulations.

The Strainprint mobile App is free and is available for both iOS & Android from the Apple iTunes and Google Play Stores, respectively. Canna Farms’ customers will receive a unique code to activate the additional features.

About Strainprint™

Founded in Toronto in 2016, StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. The Strainprint App can be downloaded from both the iOS App Store and GooglePlay Store. For more information visit www.strainprint.ca.

About Canna Farms

Canna Farms is a Health Canada Licensed Producer of craft cannabis products and was the first ACMPR Licensed Producer in British Columbia. Their team is dedicated to providing patients with exceptional cannabis products at an affordable price.

Canna Farms, 1-855-882-0988, www.cannafarms.ca

SOURCE Strainprint™ Technologies Ltd.

Media Contact

Jessica Moran
Strainprint™ Technologies Ltd
jessica.moran@strainprint.ca
(519) 494-5379

Strainprint Featured on the Investing News Network: Software Company Strainprint Wants to Change the Limitations of Medical Cannabis Research

On August 30th, 2017 Strainprint was featured on the Investing News Network. Our President, Dave Berg spoke to the Investing News Network about Strainprint and how we’re working to change the limitations of Medical Cannabis Research.

https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/software-company-strainprint-wants-change-limitations-medical-cannabis-research/